GlaxoSmithKline plc (the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||
a) |
Name |
Mr D E Troy |
||||||
b) |
Position/status |
SVP & General Counsel |
||||||
c) |
Initial notification/ amendment |
Initial notification |
||||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
a) |
Name |
GlaxoSmithKline plc |
||||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||||
b) |
Nature of the transaction |
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's US Deferred Performance Share Plan. |
||||||
c) |
Price(s) and volume(s) |
|
||||||
d) |
Aggregated information
Aggregated volume Price |
383.749 $41.02 |
||||||
e) |
Date of the transaction |
2017-10-12 |
||||||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |